These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2368728)

  • 1. A pharmaceutical manufacturer's perspective on reporting adverse drug experiences.
    Sullivan JW
    Am J Hosp Pharm; 1990 Jun; 47(6):1342-5. PubMed ID: 2368728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of adverse drug experience reports submitted by pharmacists and physicians to the FDA.
    Ahmad SR; Freiman JP; Graham DJ; Nelson RC
    Pharmacoepidemiol Drug Saf; 1996 Jan; 5(1):1-7. PubMed ID: 15088271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project--six sites, United States, January 1-June 15, 2004.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Apr; 54(15):380-3. PubMed ID: 15843786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National adverse drug reaction reporting. 1984-1989.
    Faich GA
    Arch Intern Med; 1991 Aug; 151(8):1645-7. PubMed ID: 1872669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examination of pharmacists' intention to report serious adverse drug events (ADEs) to the FDA using the theory of planned behavior.
    Gavaza P; Brown CM; Lawson KA; Rascati KL; Wilson JP; Steinhardt M
    Res Social Adm Pharm; 2011 Dec; 7(4):369-82. PubMed ID: 21272531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of efficacy of heartworm preventive products at the FDA.
    Hampshire VA
    Vet Parasitol; 2005 Oct; 133(2-3):191-5. PubMed ID: 16099105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Direct reporting of side effects by the patient: favourable experience in the first year].
    van Grootheest AC; Passier JL; van Puijenbroek EP
    Ned Tijdschr Geneeskd; 2005 Mar; 149(10):529-33. PubMed ID: 15782689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inter-rater reliability of a classification system for hospital adverse drug event reports.
    Haynes K; Hennessy S; Morales KH; Gibson GA; Barnhart C; Jaipaul CK; Linkin DR
    Clin Pharmacol Ther; 2008 Mar; 83(3):485-8. PubMed ID: 17713472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use and reported adverse effects of new chemical entities.
    Kennedy DL; Goetsch RA; Dreis MW
    Am J Hosp Pharm; 1989 Mar; 46(3):558-65. PubMed ID: 2719041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration.
    Brajovic S; Piazza-Hepp T; Swartz L; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):565-70; discussion 571-2. PubMed ID: 22359404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The quality of published adverse drug event reports.
    Kelly WN
    Ann Pharmacother; 2003 Dec; 37(12):1774-8. PubMed ID: 14632590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved reporting of adverse drug reactions.
    Kimelblatt BJ; Young SH; Heywood PM; Mandala AR; Gendelman S; Mehl B
    Am J Hosp Pharm; 1988 May; 45(5):1086-9. PubMed ID: 3400650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Form for reporting serious adverse events and product problems with human drug and biological products and devices; availability--FDA. Notice.
    Fed Regist; 1993 Jun; 58(105):31596-614. PubMed ID: 10171452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of Canadian pharmacist involvement in adverse drug reaction reporting.
    Taras-Zasowski KM; Einarson TR
    Can J Hosp Pharm; 1989 Jun; 42(3):105-8, 133. PubMed ID: 10318271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Organization and results of drug vigilance in France].
    Bégaud B; Chaslerie A; Haramburu F
    Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 20. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.
    Johann-Liang R; Wyeth J; Chen M; Cope JU
    Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):24-7. PubMed ID: 19009550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.